clement, Author at BaseLaunch

New partner announcement: BB Pureos Bioventures

We are proud to announce that BB Pureos Bioventures has become a partner in BaseLaunch Phase II as the first venture capital fund. Anja Harmeier,…

clement08.06.2020

All Features

Roche becomes a founding partner of BaseLaunch Phase II

We are proud to announce that Roche has become a founding partner in the next phase of BaseLaunch. With this commitment, Roche renews its partnership…

clement15.05.2020

All Portfolio news

Polyneuron recieves approval to begin clinical study

Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…

clement11.05.2020

All Features

Research Study Opportunity

There is an opportunity to participate in a research study interview taking place for those with knowledge of the biopharmaceutical industry in Switzerland. The research should…

clement11.05.2020

All Features

Looking for people for exciting projects

We are supporting an exciting project that exploits the role and vulnerabilities of circulating tumor cell clusters, major mediators of metastasis. The team is developing…

clement11.05.2020

All Features

Basic biotech starter kit: a flourishing ecosystem and highly focused support

“Go start a biotech company in a strong biotech ecosystem” is our conclusion from this Nature paper, which tracks down every biotech start-up emerging (between…

clement08.05.2020

All Company interviews Interviews

Featured Interview: Baselaunch chats with Silvio Bonaccio, ETH Zurich

Silvio Bonaccio is delighted by the strong entrepreneurial spirit that he encounters in his work as Head of ETH transfer. It took time, effort and…

clement08.05.2020

All Features

KPMG: COVID-19 feature- Build resilience

From our partner, KPMG: Proving an online knowledge base for the COVID-19 times. KPMG has put together an online resource page for these challenging and…

clement08.05.2020

All Portfolio news

Anaveon raises CHF 35 million

Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…

clement05.03.2020

All Portfolio news

Polyneuron raises CHF 22.5 million in Series A financing

Polyneuron Pharmaceuticals, one of our portfolio companies has successfully raised 22.5 million francs in a round of financing. The Basel-based company will use the proceeds…

clement04.03.2020

clement

New partner announcement: BB Pureos Bioventures

Roche becomes a founding partner of BaseLaunch Phase II

Polyneuron recieves approval to begin clinical study

Research Study Opportunity

Looking for people for exciting projects

Basic biotech starter kit: a flourishing ecosystem and highly focused support

Featured Interview: Baselaunch chats with Silvio Bonaccio, ETH Zurich

KPMG: COVID-19 feature- Build resilience

Anaveon raises CHF 35 million

Polyneuron raises CHF 22.5 million in Series A financing

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us